Profund Advisors LLC Blueprint Medicines Corp Transaction History

Profund Advisors LLC

$2.59 Billion
Q3 2024

A detailed history of Profund Advisors LLC transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Profund Advisors LLC holds 23,450 shares of BPMC stock, worth $2.12 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares

23,450

Previous 18,114 29.46%

Holding current value

$2.12 Million

Previous $1.95 Million 11.07%

% of portfolio

0.08%

Previous 0.07%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$84.1 - $120.5 $448,757 - $642,988	5,336 Added 29.46%	23,450 $2.17 Million
Q2 2024 Aug 13, 2024	BUY	$85.18 - $108.78 $148,128 - $189,168	1,739 Added 10.62%	18,114 $1.95 Million
Q1 2024 May 08, 2024	SELL	$73.17 - $99.79 $311,192 - $424,406	-4,253 Reduced 20.62%	16,375 $1.55 Million
Q4 2023 Feb 14, 2024	SELL	$43.96 - $92.84 $353,218 - $745,969	-8,035 Reduced 28.03%	20,628 $1.9 Million
Q3 2023 Nov 13, 2023	BUY	$46.9 - $66.0 $104,352 - $146,850	2,225 Added 8.42%	28,663 $1.44 Million
Q2 2023 Aug 10, 2023	SELL	$42.2 - $66.37 $175,636 - $276,231	-4,162 Reduced 13.6%	26,438 $1.67 Million
Q1 2023 May 11, 2023	BUY	$37.97 - $50.0 $854,400 - $1.13 Million	22,502 Added 277.87%	30,600 $1.38 Million
Q4 2022 Feb 02, 2023	BUY	$41.06 - $66.48 $6,980 - $11,301	170 Added 2.14%	8,098 $354,000
Q3 2022 Nov 04, 2022	SELL	$49.93 - $77.7 $7,439 - $11,577	-149 Reduced 1.84%	7,928 $522,000
Q2 2022 Aug 01, 2022	SELL	$45.23 - $70.15 $44,551 - $69,097	-985 Reduced 10.87%	8,077 $408,000
Q1 2022 May 10, 2022	SELL	$54.1 - $110.08 $54,532 - $110,960	-1,008 Reduced 10.01%	9,062 $579,000
Q4 2021 Feb 08, 2022	SELL	$94.25 - $115.99 $107,539 - $132,344	-1,141 Reduced 10.18%	10,070 $1.08 Million
Q3 2021 Nov 12, 2021	SELL	$80.98 - $109.47 $37,574 - $50,794	-464 Reduced 3.97%	11,211 $1.15 Million
Q2 2021 Aug 12, 2021	SELL	$82.78 - $101.0 $18,791 - $22,927	-227 Reduced 1.91%	11,675 $1.03 Million
Q1 2021 May 14, 2021	SELL	$90.71 - $108.28 $57,600 - $68,757	-635 Reduced 5.07%	11,902 $1.16 Million
Q4 2020 Feb 09, 2021	BUY	$92.08 - $124.48 $117,494 - $158,836	1,276 Added 11.33%	12,537 $1.41 Million
Q3 2020 Nov 13, 2020	SELL	$66.45 - $92.7 $109,576 - $152,862	-1,649 Reduced 12.77%	11,261 $1.04 Million
Q2 2020 Aug 03, 2020	BUY	$57.09 - $79.27 $166,988 - $231,864	2,925 Added 29.29%	12,910 $1.01 Million
Q1 2020 May 15, 2020	SELL	$48.11 - $82.22 $196,914 - $336,526	-4,093 Reduced 29.07%	9,985 $584,000
Q4 2019 Feb 18, 2020	BUY	$66.73 - $82.59 $116,710 - $144,449	1,749 Added 14.19%	14,078 $1.13 Million
Q3 2019 Nov 12, 2019	BUY	$72.9 - $101.41 $898,784 - $1.25 Million	12,329 New	12,329 $906,000

Others Institutions Holding BPMC

# of Institutions

351

Shares Held

60.3M

Call Options Held

2.25M

Put Options Held

1.18M

View Full List

About Blueprint Medicines Corp

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

More about BPMC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Profund Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Profund Advisors LLC with notifications on news.

Account

Profund Advisors LLC Blueprint Medicines Corp Transaction History